Second hematologic malignancies after ABVD: Two case reports and a retrospective study of 183 Hodgkin lymphoma patients

Leong, Carrie Kah-Lai; Ngeow, Joanne; Tan, Iain Beehuat; Quek, Richard; Tao, Miriam; Loh, Yvonne; Tan, Huey Ching; Lim, Soon Thye

doi:10.3109/02841860903253546

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In HL patients, the risk of developing secondary lung and breast cancer are highly relevant to irradiation therapy (RT). In contrast, therapy-related acute leukemia and myelodysplastic syndromes (t-AML/MDS) usually result from the application of alkylating agents (AA) in chemotherapy [13][14][15][16]. Acute leukemia has the highest relative mortality of all second malignancies [14].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies indicate that the number of chemotherapy cycles to achieve remission correlates with the risk of secondary leukemia [18][19][20]. Since the 1980s, MOPP regimen has gradually been replaced by ABVD, which contains less AA, and several multi-centered surveys suggest that ABVD led to a lower risk of developing acute leukemia as compared to MOPP [14,21,22]. Nonetheless, there are limited data concerning the incidence of hematologic malignancies following ABVD [15,23].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Aggressive Natural Killer Cell Leukemia Secondary to Hodgkin Lymphoma: a Case Report and Review of the Literature

Xu¹,

Yang²,

Fu³

et al. 2015

Chemotherapy

View full text Add to dashboard Cite

A 32-year old Chinese woman presented with high fever (39C), lymphadenopathy, hepatosplenomegaly, shortness of breath and general fatigue after initial remission of Hodgkin lymphoma (HL). The immuno-phenotype of blast cells found in her peripheral blood and pleural fluid suggested abnormal Natural Killer (NK) cells (CD2+CD3-CD56+CD45RO+HLADR+CD94+ with high Ki67). Her serum EB virus DNA was over 1.0×107IU/mL. Combining her clinical symptom and laboratory data, the patient was diagnosed with Hodgkin Lymphoma, secondary NK cell leukemia and haemophagocytic lymphohistocytosis (HLH). To date, this is the first reported case that developed secondary ANKL after the treatment of Hodgkin Lymphoma. Secondary treatment-related cancers are a major problem in HL survivors. Thus, novel treatment strategies for HL should aim at a reduction of chemotherapy and radiation therapy in order to reduce the risk for development of therapy-related malignancies. In conclusion, improvements of combined therapy as well as close monitoring during clinical follow up could warrant the improved overall survival of HL and prevent fatal complications.

show abstract